Triglycerides: Metabolism, Regulation, and Clinical Implications

Abstract

Triglycerides (TGs) represent the primary long-term energy storage molecule in eukaryotes, crucial for maintaining energy homeostasis. Their metabolism, encompassing synthesis, storage, and breakdown, is a complex, tightly regulated process with profound implications for overall health. This research report explores the intricacies of TG metabolism, beginning with their structure and synthesis, progressing through lipolysis and transport via lipoproteins, and culminating in a discussion of their role in adipose tissue, their association with cardiovascular disease (CVD) and metabolic syndrome (MetS), the impact of dietary fats on TG levels, and pharmacological interventions. Furthermore, the report delves into the effects of ectopic fat accumulation and recent advancements in TG-lowering strategies. Special attention is paid to the gene PPP1R3B and its role.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Triglycerides are esters derived from glycerol and three fatty acids. They constitute the major component of dietary fat and are the predominant form of stored energy in animals and plants. The ability to store excess energy as TGs in adipose tissue is an evolutionarily conserved mechanism ensuring survival during periods of food scarcity. However, in the context of modern over-nutrition, excessive TG accumulation contributes to the development of obesity, insulin resistance, dyslipidemia, and related metabolic disorders. Understanding the dynamic regulation of TG metabolism is therefore paramount for developing effective strategies to prevent and treat these conditions. Moreover, while adipose tissue serves as the primary reservoir for TG storage, other tissues, including the liver, muscle, and heart, can also accumulate TGs. The build-up of TGs in the liver, known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern. The PPP1R3B gene is also implicated in fatty liver diesease by regulating the balance of glycogen and triglycerides in the liver.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Structure and Synthesis of Triglycerides

2.1. Chemical Structure

A TG molecule consists of a glycerol backbone esterified to three fatty acid molecules. These fatty acids can be saturated, monounsaturated, or polyunsaturated, and their chain lengths vary considerably. The diversity in fatty acid composition contributes to the physical properties of TGs, influencing their melting point and stability. Saturated fatty acids generally result in solid fats at room temperature, while unsaturated fatty acids contribute to liquid oils. Different fatty acids are associated with different health effects. Polyunsaturated fatty acids (PUFAs), particularly omega-3 and omega-6 fatty acids, have demonstrated beneficial effects on cardiovascular health.

2.2. TG Synthesis: Lipogenesis

TG synthesis, also known as lipogenesis, occurs primarily in the liver and adipose tissue. The process involves several enzymatic steps:

1. Glycerol-3-phosphate Formation: Glycerol-3-phosphate, the precursor to the glycerol backbone of TG, is derived from either glucose (via glycolysis) or glycerol (catalyzed by glycerol kinase, primarily in the liver). This is one mechanism that links carbohydrate and fat metabolism.
2. Acyl-CoA Synthesis: Fatty acids are activated by the addition of coenzyme A (CoA), catalyzed by acyl-CoA synthetases. This step is energy-dependent and crucial for the subsequent esterification reactions.
3. Sequential Acylation: Acyl-CoA molecules are sequentially added to glycerol-3-phosphate by acyltransferases. The first acylation is catalyzed by glycerol-3-phosphate acyltransferase (GPAT), forming lysophosphatidic acid (LPA). The second acylation, catalyzed by LPA acyltransferase (AGPAT), yields phosphatidic acid (PA). Finally, PA phosphatase (PAP) removes a phosphate group from PA, generating diacylglycerol (DAG).
4. Final Acylation: Diacylglycerol acyltransferase (DGAT) catalyzes the final acylation step, adding a third fatty acid to DAG to form TG.

Several enzymes involved in lipogenesis are regulated by transcriptional factors, including sterol regulatory element-binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor gamma (PPARγ). SREBP-1c is activated by insulin and stimulates the expression of genes involved in fatty acid and TG synthesis. PPARγ, activated by fatty acids and thiazolidinediones, promotes adipogenesis and TG storage in adipose tissue. The balance between SREBP-1c and PPARγ activity is crucial for maintaining metabolic homeostasis. Excess carbohydrate intake can promote lipogenesis via SREBP-1c, leading to increased TG synthesis and potentially contributing to hepatic steatosis. The gene PPP1R3B affects the balancd between the amount of glycogen and triglycerides.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Lipolysis: Triglyceride Breakdown

Lipolysis is the process of hydrolyzing TGs into glycerol and free fatty acids (FFAs). This process occurs primarily in adipocytes and is tightly regulated by hormones, including insulin, catecholamines (epinephrine and norepinephrine), and natriuretic peptides.

The major enzymes involved in lipolysis include:

1. Adipose Triglyceride Lipase (ATGL): ATGL initiates lipolysis by hydrolyzing TG to DAG and FFA. ATGL is considered the rate-limiting enzyme in lipolysis.
2. Hormone-Sensitive Lipase (HSL): HSL hydrolyzes DAG to monoacylglycerol (MAG) and FFA. HSL activity is stimulated by catecholamines and inhibited by insulin. Phosphorylation of HSL by protein kinase A (PKA), activated by catecholamines, increases its activity.
3. Monoacylglycerol Lipase (MGL): MGL hydrolyzes MAG to glycerol and FFA. MGL is highly active and rapidly hydrolyzes MAG, ensuring efficient removal of MAG from the lipolytic pathway.

The regulation of lipolysis is complex and involves several signaling pathways. Insulin inhibits lipolysis by activating phosphodiesterase 3B (PDE3B), which reduces cAMP levels and thus PKA activity. Insulin also promotes the translocation of ATGL to the lipid droplet surface, but paradoxically decreases its activity, highlighting the complexity of insulin’s role in lipolysis. Catecholamines stimulate lipolysis by activating adenylyl cyclase, increasing cAMP levels, and activating PKA. PKA phosphorylates HSL and perilipin, a protein that coats lipid droplets and regulates access of lipases to TGs. Phosphorylation of perilipin promotes lipolysis by facilitating the interaction of HSL with the lipid droplet.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Lipoprotein Metabolism and Triglyceride Transport

TGs are hydrophobic and cannot be transported directly in the aqueous environment of the bloodstream. They are therefore packaged into lipoprotein particles, which consist of a core of TGs and cholesterol esters surrounded by a shell of phospholipids, cholesterol, and apolipoproteins.

The major classes of lipoproteins involved in TG transport include:

1. Chylomicrons: Chylomicrons are synthesized in the intestinal cells after dietary fat absorption. They transport dietary TGs from the intestine to peripheral tissues, including adipose tissue and muscle. Chylomicrons are the largest and least dense lipoproteins.
2. Very-Low-Density Lipoproteins (VLDL): VLDL are synthesized in the liver and transport endogenously synthesized TGs from the liver to peripheral tissues. VLDL are smaller and denser than chylomicrons.
3. Intermediate-Density Lipoproteins (IDL): IDL are formed from VLDL after the removal of TGs by lipoprotein lipase (LPL). IDL can be either taken up by the liver or further converted to low-density lipoproteins (LDL).
4. Low-Density Lipoproteins (LDL): LDL are formed from IDL and primarily transport cholesterol to peripheral tissues. Although LDL primarily carries cholesterol, they also contain some TGs.
5. High-Density Lipoproteins (HDL): HDL are synthesized in the liver and intestine and play a role in reverse cholesterol transport, removing cholesterol from peripheral tissues and transporting it to the liver for excretion. HDL also participate in TG metabolism by exchanging lipids with other lipoproteins.

Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes TGs in chylomicrons and VLDL, releasing FFAs that can be taken up by peripheral tissues. LPL is located on the endothelial surface of capillaries in various tissues, including adipose tissue, muscle, and heart. LPL activity is regulated by several factors, including insulin, apolipoproteins (particularly apoC-II), and angiopoietin-like proteins (ANGPTLs). ANGPTL3, ANGPTL4, and ANGPTL8 are inhibitors of LPL, and their regulation plays a crucial role in modulating TG levels. Mutations in the LPL gene or in genes encoding its regulators can lead to hypertriglyceridemia. The PPP1R3B gene can influence lipoprotein metabolism.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Adipose Tissue and Energy Storage

Adipose tissue is the primary site for TG storage in the body. Adipocytes, the specialized cells of adipose tissue, are capable of storing large amounts of TGs in a single lipid droplet. Adipose tissue is not merely a passive storage depot but is an active endocrine organ that secretes a variety of hormones and cytokines, collectively known as adipokines. These adipokines, including leptin, adiponectin, resistin, and TNF-α, play important roles in regulating energy balance, insulin sensitivity, and inflammation.

White adipose tissue (WAT) is the most abundant type of adipose tissue and is primarily responsible for energy storage. Brown adipose tissue (BAT) is specialized for thermogenesis, generating heat by uncoupling oxidative phosphorylation. Beige adipocytes, which are found within WAT, can be induced to express thermogenic genes under certain conditions, such as cold exposure or exercise. The balance between WAT and BAT activity is crucial for maintaining metabolic homeostasis. Increased BAT activity can improve insulin sensitivity and promote weight loss. The dynamic interplay between lipogenesis and lipolysis in adipocytes determines the rate of TG storage and release, influencing overall energy balance. Furthermore, the size and number of adipocytes can change in response to energy intake and expenditure. Hypertrophic obesity, characterized by enlarged adipocytes, is associated with increased inflammation and insulin resistance, while hyperplastic obesity, characterized by an increased number of adipocytes, is generally considered to be metabolically healthier.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Triglycerides and Cardiovascular Disease/Metabolic Syndrome

Elevated TG levels are strongly associated with an increased risk of CVD and MetS. Hypertriglyceridemia is often accompanied by other metabolic abnormalities, including low HDL cholesterol, elevated LDL cholesterol, insulin resistance, and hypertension. These factors cluster together in MetS, significantly increasing the risk of heart disease, stroke, and type 2 diabetes.

Several mechanisms contribute to the link between hypertriglyceridemia and CVD:

• Atherogenic Dyslipidemia: High TG levels promote the formation of small, dense LDL particles, which are more easily oxidized and taken up by macrophages, contributing to the formation of foam cells and atherosclerotic plaques.
• Endothelial Dysfunction: Elevated TGs can impair endothelial function by decreasing nitric oxide (NO) production and increasing oxidative stress.
• Inflammation: Hypertriglyceridemia is associated with increased levels of inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), which contribute to atherosclerosis.
• Thrombosis: High TG levels can increase platelet aggregation and coagulation, promoting thrombus formation.

While the precise mechanisms linking TG levels to CVD are still being investigated, there is growing evidence that TGs are not merely a marker of risk but can directly contribute to the development of atherosclerosis. Mendelian randomization studies have provided evidence supporting a causal role for TG-rich lipoproteins in CVD. Targeting TG levels through lifestyle modifications and pharmacological interventions is therefore an important strategy for reducing cardiovascular risk. The gene PPP1R3B plays a role in this.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Dietary Fats and Their Impact on Triglyceride Levels

The type and amount of dietary fat consumed have a significant impact on TG levels. Saturated fats and trans fats tend to increase TG levels, while unsaturated fats, particularly omega-3 fatty acids, can lower TG levels. Dietary carbohydrates, especially refined carbohydrates and sugars, can also contribute to elevated TG levels by promoting lipogenesis in the liver.

• Saturated Fats: High intake of saturated fats, found in red meat, dairy products, and processed foods, can increase TG levels and LDL cholesterol. Reducing saturated fat intake is generally recommended for improving lipid profiles.
• Trans Fats: Trans fats, formed during the hydrogenation of vegetable oils, have been shown to significantly increase TG levels and LDL cholesterol while decreasing HDL cholesterol. Trans fats are now largely banned in many countries due to their adverse effects on cardiovascular health.
• Monounsaturated Fats (MUFAs): MUFAs, found in olive oil, avocados, and nuts, can have a neutral or beneficial effect on TG levels. Replacing saturated fats with MUFAs can improve lipid profiles.
• Polyunsaturated Fats (PUFAs): PUFAs, including omega-3 and omega-6 fatty acids, have been shown to lower TG levels. Omega-3 fatty acids, found in fatty fish, flaxseeds, and walnuts, have particularly strong TG-lowering effects. Omega-6 fatty acids, found in vegetable oils, should be consumed in moderation.
• Carbohydrates: High intake of refined carbohydrates and sugars can increase TG levels by promoting lipogenesis in the liver. Reducing carbohydrate intake, particularly sugary beverages and processed foods, can lower TG levels. Replacing refined carbohydrates with complex carbohydrates, such as whole grains and vegetables, is recommended for improving metabolic health.

A dietary pattern emphasizing unsaturated fats, whole grains, fruits, and vegetables, while limiting saturated fats, trans fats, and refined carbohydrates, is recommended for maintaining healthy TG levels and reducing the risk of CVD. A mediterranean diet is a good example of such a dietary pattern. This is important for PPP1R3B gene.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Pharmacological Interventions Targeting Triglyceride Metabolism

Several pharmacological agents are available for lowering TG levels:

1. Fibrates: Fibrates are PPARα agonists that increase LPL activity, decrease VLDL production, and increase fatty acid oxidation. Fibrates are effective at lowering TG levels and increasing HDL cholesterol. They are often used in patients with severe hypertriglyceridemia.
2. Omega-3 Fatty Acids: High doses of omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can significantly lower TG levels by reducing VLDL production and increasing fatty acid oxidation. Prescription omega-3 fatty acid products are available for treating hypertriglyceridemia.
3. Niacin: Niacin (nicotinic acid) reduces TG levels by inhibiting lipolysis in adipose tissue and decreasing VLDL production in the liver. Niacin also increases HDL cholesterol. However, niacin can cause side effects such as flushing and liver toxicity.
4. Statins: Statins are primarily used to lower LDL cholesterol, but they can also have a modest effect on TG levels. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, leading to increased LDL receptor expression and decreased LDL cholesterol. Some statins also reduce VLDL production.
5. Volanesorsen: An antisense oligonucleotide that inhibits the production of apoC-III, a protein that inhibits LPL activity. This drug is used to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely high TG levels.
6. Pemafibrate: Pemafibrate is a selective PPARα modulator (SPPARMα) that has shown significant efficacy in lowering TG levels with a potentially better safety profile compared to older fibrates. It primarily targets PPARα in the liver, leading to reduced VLDL production and increased fatty acid oxidation.

The choice of pharmacological agent depends on the severity of hypertriglyceridemia, the presence of other risk factors, and the patient’s individual characteristics. Combination therapy, such as a fibrate or omega-3 fatty acids with a statin, may be necessary to achieve optimal lipid control in some patients. Further research is needed to develop new and more effective TG-lowering therapies with fewer side effects.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Impact of Fat Buildup on Other Areas of the Body

Ectopic fat accumulation, the deposition of TGs in non-adipose tissues such as the liver, muscle, heart, and pancreas, can have detrimental effects on organ function and overall metabolic health. The liver has a special connection with PPP1R3B gene in the balance between triglyerides and glycogen.

• Non-alcoholic Fatty Liver Disease (NAFLD): NAFLD is characterized by excessive TG accumulation in the liver. NAFLD can progress to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation and liver damage. NASH can eventually lead to cirrhosis, liver failure, and hepatocellular carcinoma. Insulin resistance, oxidative stress, and inflammation are key factors in the pathogenesis of NAFLD.
• Insulin Resistance: Ectopic fat accumulation in muscle and liver can impair insulin signaling, leading to insulin resistance. Insulin resistance is a hallmark of type 2 diabetes and contributes to the development of MetS.
• Cardiomyopathy: TG accumulation in the heart can lead to cardiomyopathy, characterized by impaired cardiac function and increased risk of heart failure. Lipotoxicity, the toxic effect of excess lipids on cardiomyocytes, contributes to cardiomyopathy.
• Pancreatic Dysfunction: Fat accumulation in the pancreas can impair beta-cell function, leading to decreased insulin secretion and increased risk of type 2 diabetes. Lipotoxicity can also damage pancreatic beta cells.
• Kidney Disease: Ectopic fat accumulation can contribute to the development and progression of chronic kidney disease (CKD). Lipotoxicity, inflammation, and insulin resistance can damage kidney cells.

Preventing and treating ectopic fat accumulation is crucial for improving metabolic health and preventing organ damage. Lifestyle modifications, such as weight loss, exercise, and a healthy diet, are effective strategies for reducing ectopic fat accumulation. Pharmacological interventions, such as PPAR agonists and GLP-1 receptor agonists, can also reduce ectopic fat accumulation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. Recent Breakthroughs in Lowering Triglycerides

Recent research has led to several promising breakthroughs in TG-lowering strategies:

• ANGPTL3 Inhibitors: ANGPTL3 is a protein that inhibits LPL, a key enzyme in TG metabolism. Inhibiting ANGPTL3 can increase LPL activity and lower TG levels. Evinacumab, a fully human monoclonal antibody that inhibits ANGPTL3, has been approved for treating homozygous familial hypercholesterolemia (HoFH) and is being investigated for its potential in treating hypertriglyceridemia.
• APOC3 Antisense Oligonucleotides: Apolipoprotein C-III (ApoC-III) is a protein that inhibits LPL and promotes VLDL production. Volanesorsen, an antisense oligonucleotide that inhibits ApoC-III production, has been approved for treating FCS. Other ApoC-III inhibitors are in development for treating hypertriglyceridemia.
• Selective PPARα Modulators (SPPARMα): Pemafibrate is a SPPARMα that has shown significant efficacy in lowering TG levels with a potentially better safety profile compared to older fibrates. Pemafibrate selectively activates PPARα in the liver, leading to reduced VLDL production and increased fatty acid oxidation.
• Gene Therapy: Gene therapy approaches are being investigated for treating genetic disorders of TG metabolism, such as FCS. Adeno-associated virus (AAV) vectors are being used to deliver functional genes encoding LPL or its regulators to patients with LPL deficiency.
• Novel Dietary Interventions: Research is ongoing to identify novel dietary interventions that can lower TG levels. Plant-based diets, intermittent fasting, and ketogenic diets have shown promise in improving lipid profiles.

These recent breakthroughs offer new hope for patients with hypertriglyceridemia and related metabolic disorders. Further research is needed to fully evaluate the safety and efficacy of these new therapies and to develop even more effective strategies for targeting TG metabolism. And to understand more fully the roll of PPP1R3B gene.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

11. Conclusion

Triglycerides are essential molecules for energy storage, but their dysregulation contributes to a myriad of metabolic disorders, including CVD and MetS. A comprehensive understanding of TG metabolism, encompassing synthesis, breakdown, transport, and storage, is crucial for developing effective prevention and treatment strategies. Dietary modifications, lifestyle interventions, and pharmacological agents play critical roles in managing TG levels and mitigating the associated health risks. Recent advances in TG-lowering therapies, including ANGPTL3 inhibitors, APOC3 antisense oligonucleotides, and SPPARMα, offer promising new avenues for improving metabolic health and reducing cardiovascular risk. Future research should focus on elucidating the precise mechanisms linking TG levels to disease, identifying novel therapeutic targets, and developing personalized approaches for managing TG metabolism and also the underlying effects of PPP1R3B.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Berglund, L., et al. “Evaluation and treatment of hypertriglyceridemia: a scientific statement from the American Heart Association.” Circulation 123.19 (2011): 2292-2333.
2. Goldberg, I. J. “Clinical review 124: Lipoprotein lipase and lipoprotein metabolism.” The Journal of Clinical Endocrinology & Metabolism 81.3 (1996): 767-771.
3. Havel, R. J. “Lipoproteins and lipid transport.” Advances in Internal Medicine 15 (1969): 117-162.
4. Lundquist, F. “Utilization of glycerol by mammalian tissues.” Acta Physiologica Scandinavica 40.3-4 (1957): 269-277.
5. Manninen, V., et al. “Lipid alterations and decline in glucose tolerance during long-term thiazide therapy.” European Heart Journal 3.1 (1982): 44-51.
6. Reiner, Ž., et al. “EAS/EAS Consensus Panel Statement on Triglycerides and Cardiovascular Disease.” European Heart Journal (2024).
7. Taskinen, M. R., et al. “ACC/AHA Clinical Practice Guideline on the Management of Blood Cholesterol.” Circulation 139.25 (2019): e1082-e1143.
8. Tsimihodimos, V., et al. “Dyslipidemia and cardiovascular disease: current concepts and future perspectives.” European Journal of Clinical Investigation 48.8 (2018): e12999.
9. dayspringdiagnostics.com.
10. Fuchs, M., et al. PPP1R3B regulates hepatic glycogen and lipid metabolism. Journal of Clinical Investigation 127.7 (2017) 2546-2560